SeaGen Promotes Dobmeier

6/17/11

Seattle Genetics (NASDAQ: SGEN), the Bothell, WA-based developer of targeted cancer drugs, said today that Eric Dobmeier has been promoted from chief business officer to chief operating officer. Dobmeier, who joined the company in 2002, has overseen the company’s efforts to license out its technology for linking antibodies to toxins that make them more potent against cancer. The biggest deal on his watch has been the alliance with Millennium: The Takeda Oncology Company, in which the companies divvied up commercial rights to brentuximab vedotin (Adcetris), as a new treatment for rare lymphomas.

By posting a comment, you agree to our terms and conditions.